Abstract 554P
Background
Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) is a useful diagnostic modality for thoracic lymphadenopathies, including primary lung cancer. However, the specimens obtained are often small and inadequate for pathological diagnosis. We previously reported that using the EchoTip ProCore Endobronchial HD ultrasound needle (EchoTip) increased the tissue diagnosis rate in lung cancer (Miyazaki et al., 2021). In previous studies, the Oncomine Dx Target Test (ODxTT) was performed in only one case, and it is unclear whether the specimens collected could tolerate next-generation sequencing (NGS)-based testing.
Methods
We performed a single-center, retrospective observational study. This study included patients who underwent ODxTT between April 1, 2019 and April 30, 2023. Patients were selected and divided into two groups comprising those who underwent EBUS-TBNA and those whose specimens were obtained by other methods. The ODxTT success rate was calculated for each group. This study was approved by the institutional review board in June 2022. (No. 22-06-05).
Results
We enrolled 144 patients:20 in the EBUS-TBNA group and 124 in the other-methods group. In the EBUS-TBNA group, the pathological diagnoses were adenocarcinoma (Ad), squamous cell carcinoma (Sq), and others in 15, 2, and 3 patients, respectively. In contrast, in the other-methods group, the collection methods were endobronchial biopsy and transbronchial biopsy, surgical procedures, computed tomography-guided needle biopsy, and others for 79, 31, 6, and 8 patients, respectively, and the pathological diagnoses were Ad, Sq, and others in 78, 15, and 31 patients, respectively. The success rates of ODxTT for EBUS-TBNA and others were 90% and 86%, respectively. The DNA and RNA inspection success rates of EBUS-TBNA were 95% and 90%, respectively, and those of the other methods were 90% and 94%, respectively.
Conclusions
The success rate of ODxTT on EBUS-TBNA specimens were 90%. It is expected to yield specimens of sufficient quality and quantity to perform ODxTT and may be an important diagnostic option in lung cancer cases with enlarged lymph nodes.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
K. Miyazaki: Financial Interests, Personal, Invited Speaker: AstraZeneca, Merck KGaA, Eli Lilly Japan K.K., Cook Medical Japan; Financial Interests, Institutional, Research Grant: AbbVie GK, MSD, AstraZeneca, Bristol Myers Squibb, Taiho Pharmaceutical CO., LTD. K. Ito, A. Hayashi: Financial Interests, Institutional, Research Grant: Taiho Pharmaceutical CO., LTD., MSD, AstraZeneca, Bristol Myers Squibb, AbbVie GK. A. Shiba: Financial Interests, Institutional, Research Grant: AstraZeneca, MSD, Taiho Pharmaceutical CO., LTD., Bristol Myers Squibb, AbbVie GK. Y. Higashi: Financial Interests, Institutional, Research Grant: Taiho Pharmaceutical CO., LTD., MSD, AstraZeneca, Bristol Myers Squibb, AbbVie GK. M. Aga: Financial Interests, Personal, Invited Speaker: TEIJIN PHARMA, Nippon Boehringer Ingelheim Co., Ltd.; Financial Interests, Institutional, Research Grant: AbbVie GK, Bristol Myers Squibb, Taiho Pharmaceutical CO., LTD., MSD, AstraZeneca. Y. Hamakawa: Financial Interests, Institutional, Research Grant: Taiho Pharmaceutical CO., LTD., Chugai Pharmaceutical CO., LTD, Ono Pharmaceutical CO., LTD., AstraZeneca, AbbVie GK. Y. Taniguchi: Financial Interests, Institutional, Research Grant: Taiho Pharmaceutical CO., LTD., MSD, Bristol Myers Squibb, AstraZeneca, AbbVie GK; Financial Interests, Personal, Invited Speaker: AstraZeneca, Chugai Pharmaceutical CO., LTD, Ono Pharmaceutical CO., LTD. Y. Misumi: Financial Interests, Personal, Invited Speaker: AstraZeneca, Chugai Pharmaceutical CO., LTD, Ono Pharmaceutical CO., LTD., Nippon Kayaku CO., LTD., Taiho Pharmaceutical CO., LTD.; Financial Interests, Institutional, Research Grant: MSD, AstraZeneca, Bristol Myers Squibb, AbbVie GK, Taiho Pharmaceutical CO., LTD. Y. Agemi: Financial Interests, Personal, Invited Speaker: AstraZeneca, Chugai Pharmaceutical CO., LTD, Ono Pharmaceutical CO., LTD., Bristol Myers Squibb, Takeda Pharmaceutical Company Limited, Kyowa Hakko Kirin Co., Ltd.; Financial Interests, Institutional, Research Grant: AstraZeneca, Bristol Myers Squibb, AbbVie GK, Taiho Pharmaceutical CO., LTD., MSD. Y. Nakamura: Financial Interests, Personal, Invited Speaker: AstraZeneca, Chugai Pharmaceutical CO., LTD, Taiho Pharmaceutical CO., LTD.; Financial Interests, Institutional, Research Grant: AstraZeneca, Taiho Pharmaceutical CO., LTD., MSD, Bristol Myers Squibb, AbbVie GK. T. Shimokawa: Financial Interests, Institutional, Research Grant: Taiho Pharmaceutical CO., LTD., MSD, Bristol Myers Squibb, AstraZeneca, AbbVie GK. H. Okamoto: Financial Interests, Institutional, Research Grant: MSD, Taiho, Bristol Myers Squibb.
Resources from the same session
163P - Chemotherapy versus palliative radiotherapy in advanced inoperable gall bladder cancer
Presenter: Vimal Sekar
Session: Poster Display
Resources:
Abstract
164P - Neoadjuvant immune checkpoints inhibitors plus chemoradiotherapy for patients with locally advanced esophageal squamous cell carcinoma
Presenter: Ming-Wei Kao
Session: Poster Display
Resources:
Abstract
165P - BMI impact on the prognosis of unresectable HCC patients receiving first-line lenvatinib or atezolizumab plus bevacizumab
Presenter: Elisabeth Amadeo
Session: Poster Display
Resources:
Abstract
166P - Preoperative risk factors strongly related to early recurrence after R0 resection of gallbladder cancer
Presenter: SANGHUN LEE
Session: Poster Display
Resources:
Abstract
167P - Peripheral blood neutrophil-to-lymphocyte ratio correlated with serum IL-8 level and predict the outcome of hepatocellular carcinoma patients treated with immune-targeted combination therapy
Presenter: Xuenan Peng
Session: Poster Display
Resources:
Abstract
168P - Real-world clinicopathological characteristics and treatment patterns of esophageal cancer patients in China
Presenter: Zhihao Lu
Session: Poster Display
Resources:
Abstract
169P - Conversion response and prognostic factors in HCC patients with macrovascular invasion treated with atezolizumab plus bevacizumab
Presenter: xiaodong Zhu
Session: Poster Display
Resources:
Abstract
170P - Atezolizumab plus bevacizumab (A+B) versus lenvatinib for BCLC-B stage of patients with hepatocellular carcinoma (HCC): A large real-life worldwide population
Presenter: Francesco Vitiello
Session: Poster Display
Resources:
Abstract
171P - Retrospective study of the correlation between proteinuria and renal function in patients (pts) with unresectable hepatocellular carcinoma (uHCC) treated with atezolizumab plus bevacizumab (Atezo+Bev): ARISE study
Presenter: Kazuomi Ueshima
Session: Poster Display
Resources:
Abstract
172P - Trastuzumab deruxtecan (T-DXd) in Chinese patients (pts) with previously treated HER2-positive locally advanced/metastatic gastric cancer (GC) or gastroesophageal junction adenocarcinoma (GEJA): Primary efficacy and safety from the phase II single-arm DESTINY-Gastric06 (DG06) trial
Presenter: Zhi Peng
Session: Poster Display
Resources:
Abstract